Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 4/20 | 0.42 |
| ▸ | EHMT2 | Q96KQ7 | 6/20 | 0.41 |
| ▸ | EHMT1 | Q9H9B1 | 6/20 | 0.41 |
| ▸ | HTR6 | P50406 | 7/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HTR1B | P28222 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR7 | P34969 | 1/20 | 0.38 |
| ▸ | HTR3A | P46098 | 1/20 | 0.38 |
| ▸ | INPPL1 | O15357 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17154231 | 0.92 | HTR2C (0.51) | HTR2CHTR6SIGMAR1MAPTHTR1B | |
| SCHEMBL17155483 | 0.85 | HTR6 (0.46) | HTR2CEHMT2EHMT1HTR6SIGMAR1 | |
| SCHEMBL17154239 | 0.81 | HTR2C (0.41) | HTR2CEHMT2EHMT1HTR6SIGMAR1 | |
| SCHEMBL17155164 | 0.77 | HTR2C (0.55) | HTR2CHTR6SIGMAR1MAPTHTR1B | |
| SCHEMBL14704899 | 0.69 | SIGMAR1 (0.79) | HTR2CHTR6SIGMAR1MAPTHTR1B | |
| SCHEMBL20841540 | 0.69 | RGS12 (0.31) | — | |
| SCHEMBL4329636 | 0.69 | HTR2C (0.60) | HTR2CEHMT2EHMT1HTR6SIGMAR1 | |
| SCHEMBL17154240 | 0.67 | S1PR1 (0.41) | HTR2CHTR2A | |
| SCHEMBL17154233 | 0.67 | PRCP (0.46) | HTR2CHTR2A | |
| SCHEMBL14704909 | 0.66 | HTR2C (0.82) | HTR2CSIGMAR1HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9388179-B2 | N-substituted indazole sulfonamide compounds with selective activity in voltage-gated sodium channels | MERCK SHARP & DOHME CORP. (US) | 2016-07-12 | — | — | US | disclosed |
| US-20150284389-A1 | N-SUBSTITUTED INDAZOLE SULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | MERCK SHARP & DOHME CORP. (US) | 2015-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150284389-A1 | N-SUBSTITUTED INDAZOLE SULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | SCN1B, SCN1A, SCN2B | HTR2C 436/4885EHMT2 2834/4885EHMT1 2474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.